GET DAILY SIGNALSAlamar Biosciences (ALMR) Delivers +68% Revenue Growth in Q3 2026
Key Takeaways
- Alamar Biosciences reported third quarter 2026 revenue of $33.5 million, up 68% year over year and above the consensus estimate of about $30.1 million.
- Net loss narrowed to $0.19 per share, beating the consensus expectation of a $0.22 loss per share.
- Gross margin expanded to 61.5% from 59.7% a year earlier, helped by a favorable shift toward higher-margin consumables.
- The company raised its full-year 2026 revenue outlook to $121 million to $123 million, up from a prior range of $116 million to $120 million.
- Cash, cash equivalents, short-term investments and restricted cash totaled $231.5 million at quarter-end, supporting continued commercial expansion.
Why This Quarter Matters
Alamar Biosciences, a commercial-stage precision proteomics company, went public in April 2026 and is still building its investor track record. Its ARGO HT System and NULISA assay technology target the detection of protein biomarkers at very low concentrations in blood, with a focus on early disease detection. The third quarter provides key insight into whether the installed base of instruments is driving recurring, higher-margin consumables revenue. In my view, investors are right to watch gross margin, cash burn, and full-year guidance closely as signals of efficient scaling. With rising operating expenses tied to headcount, infrastructure, and R&D, this report clarifies whether top-line momentum supports a credible path toward profitability.
Breaking Down the Reported Results
For the third quarter of 2026, Alamar Biosciences reported total revenue of $33.5 million, a 68% increase from $19.9 million in the prior-year period and above the consensus estimate of approximately $30.1 million. Growth was broad-based: instrument revenue rose 50% to $8.5 million, consumables revenue grew 79% to $17.8 million, and services and other revenue increased 69% to $7.2 million.
Gross margin expanded to 61.5%, up from 59.7% a year earlier, reflecting lower instrument costs, higher average selling prices for consumables, and a favorable product mix. Net loss for the quarter was $13.3 million, or $0.19 per share, narrower than the consensus expectation of a $0.22 loss per share. Operating expenses rose 81% to $35.8 million on planned investments in headcount, infrastructure, and R&D, as well as incremental public-company costs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Management raised full-year 2026 revenue guidance to a range of $121 million to $123 million, up from $116 million to $120 million, implying roughly 64% growth at the midpoint versus 2025. The company ended the quarter with $231.5 million in cash, cash equivalents, short-term investments and restricted cash.
Market Reaction and Investor Sentiment
Alamar Biosciences shares traded higher in the session following the November 3 release, with the stock advancing around 4% as investors responded to the revenue beat and the upward revision to full-year guidance. The reaction is notable because the stock had been under pressure in the weeks before the report, having declined roughly 24% over the prior month. Heading into the print, sentiment was cautious, with analysts projecting a loss of $0.22 per share on about $30.1 million in revenue. The beat on both revenue and EPS, combined with stronger-than-expected consumables and services revenue, appears to have reassured investors about the durability of demand across the company’s proteomics platform. Still, the company remains unprofitable, and the sharp rise in operating expenses is a key area of investor scrutiny.
Forward Outlook and Key Factors to Monitor
Following the raised guidance, investors will focus on whether Alamar can sustain its instrument placement momentum and convert new placements into recurring consumables demand. Consumables revenue growth of 79% year over year is a positive signal, but the durability of that growth depends on utilization across an expanding installed base.
Cost trends will also be closely watched. Operating expenses rose 81% year over year, reflecting planned investments in headcount, infrastructure, and R&D. As the company scales, investors will look for signs that spending growth begins to moderate relative to revenue, which would support the path toward narrowing losses.
Another factor to monitor is leadership continuity. Alamar announced that President Tod White will retire at the end of 2026 and remain as an advisor through June 2027, a transition that investors may weigh against the company’s commercial and operational momentum.
Finally, strategic and regulatory milestones remain important catalysts. The company continues to pursue collaborations and broader clinical diagnostics ambitions, including efforts aimed at future authorization for clinical diagnostic use. Progress on those fronts, alongside sustained cash discipline, will likely shape the stock’s next leg. From what I see, this is important because it ties directly to long-term execution.
Using AI Tools for Deeper Analysis
In my analysis of names like ALMR, I often turn to Tickeron’s AI-powered tools to cross-check patterns and fundamentals against peers. This helps put the quarter’s results into broader context without relying solely on manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALMR in downward trend: price dove below 50-day moving average on October 30, 2026
ALMR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 1 of 1 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ALMR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 3 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 4 of 5 cases where ALMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ALMR as a result. In 8 of 8 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ALMR just turned positive on October 21, 2026. Looking at past instances where ALMR's MACD turned positive, the stock continued to rise in 2 of 2 cases over the following month. The odds of a continued upward trend are 90%.
Following a +12.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMR advanced for three days, in 30 of 32 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ALMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.419) is normal, around the industry mean (4.204). P/E Ratio (-40.436) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (20.367) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ALMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement